Ruti Aga banned for six years: a family member's forged prescription ends an Olympic dream

Six years, two cases, one forged document

The Athletics Integrity Unit (AIU) has banned Ethiopian marathon runner Ruti Aga for six years. According to the agency's statement issued on Thursday, the sanction runs from 10 September — the same date on which she was provisionally suspended. The six-year term is not the product of a single decision but the sum of two separate violations.

The case begins with a half marathon in China in March, which Aga won. A sample collected after that race returned an adverse analytical finding for methylprednisolone. The athlete then cited a knee injury and claimed she had been treated for it. During the investigation, a prescription was submitted that had been issued by a family member — a person with no medical registration, who claimed to have used an old prescription pad from a former workplace. The clinic named on the prescription did not exist.

The case therefore split in two. First, presence of a prohibited substance, which drew a two-year sanction. Second, tampering with evidence and misleading statements during the investigation, which drew four years. Together, six.

It is important to be clear about what this report is not. It contains almost no performance content. There is no time for the Chinese half marathon, no splits, no field quality. Any judgement about form would be fabrication. What the story actually contains is the arithmetic of the sanction and the question of how one forged document destroyed a defence that might otherwise have worked.

Two plus four: what the arithmetic tells us

The structure of the sanction is the key to this case. Two years for presence, four years for tampering, six in total.

That arithmetic tells us three things. First, the panel found the presence violation proven but did not place it at the most aggravated level of deliberate cheating, otherwise the presence sanction would have been longer. Second, the panel rejected the No Significant Fault or Negligence argument — had it been accepted, the presence sanction would have been substantially reduced, potentially to a reprimand. Third, the tampering was attributed entirely to the athlete with no mitigation.

There is an interesting near-paradox. A forged document is itself circumstantial evidence of an intent to conceal. Yet it did not aggravate the presence sanction — it was counted separately. That is simply how the Code is structured: the two violations are independent and add up.

Backdating to 10 September is no relief. Time served under provisional suspension counts against the ban, so the athlete gains nothing in real terms. It is procedural housekeeping, not a reduction.

What the substance was — and what the media called it

A technical correction is necessary here, because the original report gets it badly wrong.

Methylprednisolone was described as a "prohibited steroid" and said to be classed as performance enhancing by WADA. That is imprecise. Methylprednisolone is a glucocorticoid, not an anabolic steroid. On the WADA Prohibited List it sits in class S9, not S1. And under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes.

The implication is straightforward: a therapeutic knee injection administered out-of-competition is entirely legal. It becomes a violation only if residues are present in an in-competition sample. The entire case therefore hinged on route and timing, not on "steroid use".

The 2026 change to the Prohibited List made this position explicit — an injected glucocorticoid in-competition is a strict violation. That rule hurts most those athletes who take a painkilling injection a few days before a race and assume they are fine. In road racing the testing window opens at 23:59 the day before the race, so an injection given days earlier can still be caught.

This is precisely where Aga had a defence. Genuine medical records, with the date of injection, the route and the clinical justification, could have reduced the presence charge considerably — and the tampering charge would never have existed.

The knee: a real root cause, but a legally fatal story

Intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners. Chronic knee pathology is a well-known load-bearing failure mode in high-volume marathon training. Technically, the story is entirely plausible.

And that plausibility is exactly what makes it so damaging. When a defence is real, it is proven with real records — clinic notes, the doctor's registration, the treatment date, the dose, the route. None of that was present. A true story does not need to be manufactured. The attempt to manufacture it is itself a signal that the underlying record did not exist.

So the knee is the right place to point the finger, but it is bigger than one athlete's problem. Injured marathoners face strong pressure to mask pain because appearance-fee income depends on turning up. Glucocorticoids are the cheapest, most available tool for that. And when the surrounding medical network is informal, a forged document is what falls out of the gap.

Three layers of forgery

There are three independent verification failures here, each serious on its own.

First, the clinic named on the prescription did not exist. Second, the person who issued it had no medical registration; he was a family member. Third, he claimed to have used an old prescription pad from a former workplace, and the clinic explicitly disowned that claim.

Taken together the picture is clear: this was not a filing error or a form filled in by mistake. It was a deliberately manufactured document. It also tells us something about the support structure the athlete was operating in — evidently without a credentialed team physician.

Why there was no TUE

A properly managed athlete had two legitimate routes. First, obtain or apply for a Therapeutic Use Exemption if a prohibited route was needed to treat the knee. Second, observe WADA's route-specific washout period, leaving enough time between the injection and the race.

Neither appears to have happened. That is itself a signal: where there was no TUE and no washout calculation, there was nothing solid to fall back on when the sample came back positive. And what replaced a solid defence was a forged document.

The absence of a TUE is not automatically a fault. In many cases no TUE is needed if the timing is handled correctly. But once a case is in dispute, genuine medical records are the only defence. Here there were none.

Career arithmetic: 32 now, 38 at return

Aga is 32. When the six-year ban expires she will be close to 38. Ethiopia's women's marathon depth is such that a 38-year-old with a doping record and a long absence from competition is, for practical purposes, unselectable. The 2028 Olympic cycle is gone entirely.

In real terms this is not a six-year ban; it is the end of an elite career.

Her record, however, does not disappear. The 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors are the record of a genuinely elite marathoner. Widely reported personal bests are around 2:18:34 (Berlin 2026, second) and 2:20:40 (Tokyo 2026, first), though these figures do not appear in the source article and should be independently verified.

One thing the report leaves unstated is the scope of disqualification. Standard AIU practice is to annul the result and prize money from the competition where the sample was collected — here the March half marathon in China. Results before that date, including the 2026 Tokyo title, are not automatically annulled absent evidence of earlier use. The report gives no such evidence.

Commercially, her standing is now bifurcated: the record survives, but she is radioactive to sponsors in a sport where distance-running sponsorship is already thin.

Ethiopian depth: one athlete's removal is invisible

The competitive landscape is essentially unaffected. Ethiopia and Kenya both have such depth in the women's marathon that a 2:18 performer is not automatically selectable. The pipeline keeps producing, and the altitude-based club and agent system has very high throughput.

That does not make the case unimportant. It makes the governance question the real subject. Aga's three Major second places were commercial-tier results, not championship conversions. The departure of a 32-year-old with no global championship medals changes nothing in Ethiopian selection calculus.

What both nations share, however, is an entourage-level medical governance weakness. The deeper the talent pool, the faster informal support structures multiply, because demand is high and oversight is low.

China's label circuit: the appearance-fee economy meets the testing economy

The March race was almost certainly a World Athletics Label road race — otherwise no AIU test would have been there. The article does not name it, so this is inference at medium-high confidence.

The key point is that Asian label races have long been a lucrative, low-risk income tier for East African marathoners between Majors. Appearance fees are good, the competitive pressure is lower than at a Major, and the conditions are favourable. That is precisely the tier where the AIU now concentrates attention.

So two economies collide in the same race — the appearance-fee economy and the testing economy. What was once a safe income stream is now a risk zone.

The AIU's shifting focus: from detection to document verification

One of the biggest signals here is that the four-year tampering sanction came from an interview, not from a document alone. Statements made under questioning made the sanction heavy.

That is a pattern. Many East African road-racing cases begin with a substance violation and then acquire a fabricated or altered explanation on top. The enforcement frontier is shifting from detection toward document verification.

Aga's case is not an outlier; it belongs to a recognisable family. If so, more similarly profiled cases are likely in the pipeline, because informal medical networks serve many athletes in the same training clusters. That is medium-confidence inference and needs verification.

Is the sanction disproportionate?

Six years for a glucocorticoid — a substance with no proven endurance benefit — is a striking outcome. It will be cited both as evidence of AIU rigour and as evidence of disproportionate enforcement against African road runners.

In this case, though, that argument is weak. Four of the six years are not for the substance but for forging a document and misleading an investigation. If the bulk of the sanction is tampering, the claim that "six years for a glucocorticoid is excessive" misses the point.

This is where the original report's technical error does real damage. A reader who believes methylprednisolone is an anabolic steroid will compare this to testosterone or trenbolone cases — a false comparison. The correct comparison is with road-racing cases involving injury treatment, timing errors, and then fabricated paperwork.

Appeal: a route exists, but limited value

With the AIU's announcement on Thursday and the ban running from 10 September, the case is at the decision stage. Ordinarily a window opens to appeal to the Court of Arbitration for Sport once the reasoned decision is issued — typically around 21 days.

But the value of an appeal here is low. The tampering finding is document-based: a clinic that does not exist, an unregistered issuer, and an "old pad" the clinic explicitly disowned. That kind of finding is very hard to overturn.

There is another risk the report does not address: forging a document is not only a sports-rule matter. It may fall within criminal definitions under national law. The AIU's jurisdiction is limited to sports rules, but referral to national authorities is not unusual. No such referral is reported, but the possibility remains open.

What to watch next

First, whether Aga appeals to CAS or accepts the sanction. In a document-based case, acceptance is more likely.

Second, whether the March half marathon result and prize money are formally annulled. That is standard practice, but there is no public confirmation in this specific case.

Third, whether an agent or management is investigated. The AIU statement names only the family member. It does not say whether any agent or management role was examined. That is the most important unanswered part of this case — because an athlete does not operate alone; she operates inside a structure.

Fourth, whether the Ethiopian federation issues any statement. The report quotes only the AIU, nothing at national level.

Conclusion: the story is about paper, not running

There is almost nothing about running in this report. No time, no splits, no field quality. Any performance conclusion drawn from it would be improper.

But what it does contain is bigger than that. An athlete who had a legitimate defence — route, timing, medical necessity — chose forged documents over real ones. The result was that the strongest part of that defence, the argument that she had not taken a performance-enhancing drug, destroyed itself.

And that one decision — costing no money, no technology, no effort, only a piece of paper — turned into six years. Two became six. The last years of her prime became the last years of her career.

This is an individual failure. But leaving it at that would be damaging for the sport. When a 32-year-old elite runner believes her options are a credentialed physician, a legitimate TUE process and correct washout guidance — and still picks an old prescription pad for her alibi — the question is not why she did it. The question is why nobody around her offered her the easy, legal route.

Until that question is asked, cases like this will keep coming.